Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Sep 28

PMID 34572748

Citations 24

Authors

Carlo Cattrini

Rodrigo Espana

Alessia Mennitto

Melissa Bersanelli

Elena Castro

David Olmos

David Lorente

Alessandra Gennari

Affiliations

Soon will be listed here.

Abstract

The treatment landscape of advanced prostate cancer has completely changed during the last decades. Chemotherapy (docetaxel, cabazitaxel), androgen-receptor signaling inhibitors (ARSi) (abiraterone acetate, enzalutamide), and radium-223 have revolutionized the management of metastatic castration-resistant prostate cancer (mCRPC). Lutetium-177-PSMA-617 is also going to become another treatment option for these patients. In addition, docetaxel, abiraterone acetate, apalutamide, enzalutamide, and radiotherapy to primary tumor have demonstrated the ability to significantly prolong the survival of patients with metastatic hormone-sensitive prostate cancer (mHSPC). Finally, apalutamide, enzalutamide, and darolutamide have recently provided impactful data in patients with nonmetastatic castration-resistant disease (nmCRPC). However, which is the best treatment sequence for patients with advanced prostate cancer? This comprehensive review aims at discussing the available literature data to identify the optimal sequencing approaches in patients with prostate cancer at different disease stages. Our work also highlights the potential impact of predictive biomarkers in treatment sequencing and exploring the role of specific agents (i.e., olaparib, rucaparib, talazoparib, niraparib, and ipatasertib) in biomarker-selected populations of patients with prostate cancer (i.e., those harboring alterations in DNA damage and response genes or ).

Citing Articles

Strategic Advances in Combination Therapy for Metastatic Castration-Sensitive Prostate Cancer: Current Insights and Future Perspectives.

Kwon W, Song Y, Lee M Cancers (Basel). 2024; 16(18).

PMID: 39335158 PMC: 11430187. DOI: 10.3390/cancers16183187.

Plasma microRNA Signature as Companion Diagnostic for Abiraterone Acetate Treatment in Metastatic Castration-Resistant Prostate Cancer: A Pilot Study.

Detassis S, Precazzini F, Grasso M, Del Vescovo V, Maines F, Caffo O Int J Mol Sci. 2024; 25(11).

PMID: 38891761 PMC: 11171781. DOI: 10.3390/ijms25115573.

Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients.

Cattrini C, Manfredi M, Barboro P, Ghirimoldi M, Mennitto A, Martini V Sci Rep. 2023; 13(1):17791.

PMID: 37853018 PMC: 10585001. DOI: 10.1038/s41598-023-44157-9.

Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews.

Leaning D, Kaur G, Morgans A, Ghouse R, Mirante O, Chowdhury S Front Oncol. 2023; 13:1240864.

PMID: 37829336 PMC: 10565658. DOI: 10.3389/fonc.2023.1240864.

Emerging Immunotherapy Approaches for Treating Prostate Cancer.

Meng L, Yang Y, Mortazavi A, Zhang J Int J Mol Sci. 2023; 24(18).

PMID: 37762648 PMC: 10531627. DOI: 10.3390/ijms241814347.

References

Sydes M, Spears M, Mason M, Clarke N, Dearnaley D, de Bono J . Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018; 29(5):1235-1248. PMC: 5961425. DOI: 10.1093/annonc/mdy072. View

Mateo J, Seed G, Bertan C, Rescigno P, Dolling D, Figueiredo I . Genomics of lethal prostate cancer at diagnosis and castration resistance. J Clin Invest. 2019; 130(4):1743-1751. PMC: 7108902. DOI: 10.1172/JCI132031. View

Srinivas S, Iagaru A . To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy. J Nucl Med. 2021; 62(11):1487-1488. PMC: 8612330. DOI: 10.2967/jnumed.121.263035. View

Berthold D, Pond G, Soban F, de Wit R, Eisenberger M, Tannock I . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008; 26(2):242-5. DOI: 10.1200/JCO.2007.12.4008. View

Robinson D, Van Allen E, Wu Y, Schultz N, Lonigro R, Mosquera J . Integrative clinical genomics of advanced prostate cancer. Cell. 2015; 161(5):1215-1228. PMC: 4484602. DOI: 10.1016/j.cell.2015.05.001. View

Vlachostergios P, Puca L, Beltran H . Emerging Variants of Castration-Resistant Prostate Cancer. Curr Oncol Rep. 2017; 19(5):32. PMC: 5479409. DOI: 10.1007/s11912-017-0593-6. View

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J . Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016; 17(9):1306-16. DOI: 10.1016/S1470-2045(16)30173-5. View

Nakazawa M, Lu C, Chen Y, Paller C, Carducci M, Eisenberger M . Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015; 26(9):1859-1865. PMC: 4551160. DOI: 10.1093/annonc/mdv282. View

Abida W, Cheng M, Armenia J, Middha S, Autio K, Vargas H . Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2018; 5(4):471-478. PMC: 6459218. DOI: 10.1001/jamaoncol.2018.5801. View

10.

Aparicio A, Harzstark A, Corn P, Wen S, Araujo J, Tu S . Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013; 19(13):3621-30. PMC: 3699964. DOI: 10.1158/1078-0432.CCR-12-3791. View

11.

de Bono J, De Giorgi U, Nava Rodrigues D, Massard C, Bracarda S, Font A . Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. Clin Cancer Res. 2018; 25(3):928-936. DOI: 10.1158/1078-0432.CCR-18-0981. View

12.

Maughan B, Kessel A, McFarland T, Sayegh N, Nussenzveig R, Hahn A . Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist. 2021; 26(12):1006-e2129. PMC: 8649019. DOI: 10.1002/onco.13949. View

13.

Parker C, Nilsson S, Heinrich D, Helle S, OSullivan J, Fossa S . Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369(3):213-23. DOI: 10.1056/NEJMoa1213755. View

14.

Filippi L, Spinelli G, Chiaravalloti A, Schillaci O, Equitani F, Bagni O . Prognostic Value of F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223. Biomedicines. 2020; 8(12). PMC: 7760591. DOI: 10.3390/biomedicines8120555. View

15.

Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M . Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol. 2013; 31(14):1748-57. PMC: 3641696. DOI: 10.1200/JCO.2012.43.1882. View

16.

Hamid A, Gray K, Shaw G, Macconaill L, Evan C, Bernard B . Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. Eur Urol. 2018; 76(1):89-97. DOI: 10.1016/j.eururo.2018.11.045. View

17.

Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S . Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020; 383(24):2345-2357. DOI: 10.1056/NEJMoa2022485. View

18.

Francini E, Montagnani F, Nuzzo P, Gonzalez-Velez M, Alimohamed N, Rosellini P . Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Netw Open. 2021; 4(7):e2116536. PMC: 8299314. DOI: 10.1001/jamanetworkopen.2021.16536. View

19.

Messina C, Messina M, Cattrini C . From astrology to prostate cancer: what is the role of subgroup analyses?. Ann Oncol. 2020; 31(3):437-438. DOI: 10.1016/j.annonc.2019.11.012. View

20.

Lozano R, Castro E, Aragon I, Cendon Y, Cattrini C, Lopez-Casas P . Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer. 2020; 124(3):552-563. PMC: 7851123. DOI: 10.1038/s41416-020-01114-x. View